B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis

Biomarkers in Medicine

Volumn 8, Issue 3, 2014, Pages 395-403

  Peng, Qing Lin ^a   Shu, Xiao Ming ^a   Wang, Dong Xue ^a   Wang, Yan ^a   Lu, Xin ^a   Wang, Guo Chun ^a  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

B cell activating factor; cytokine; dermatomyositis; disease activity; polymyositis

Indexed keywords

AZATHIOPRINE; B CELL ACTIVATING FACTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; BIOLOGICAL MARKER;

ADULT; ARTHRITIS; ARTICLE; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHINESE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE DURATION; DYSPHAGIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MYOSITIS DISEASE ACTIVITY ASSESSMENT VISUAL ANALOG SCALES; ONSET AGE; POLYMYOSITIS; RATING SCALE; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; SEROLOGY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; AGED; BLOOD; METABOLISM; MIDDLE AGED;

ADULT; AGED; B-CELL ACTIVATING FACTOR; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DERMATOMYOSITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; POLYMYOSITIS;

EID: 84898482242     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.124     Document Type: Article

References (28)

1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 362, 971-982 (2003).
2. Plotz PH, Rider LG, Targoff IN et al. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann. Intern. Med. 122, 715-724 (1995).
3. Sanner H, Gran JT, Sjaastad I, Flato B. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 48, 1541-1547 (2009).
4. Stone KB, Oddis CV, Fertig N et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 56, 3125-3131 (2007).
5. Fathi M, Barbasso HS, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J. Intern. Med. 271, 589-597 (2012).
6. Bolgarin RN, Rodnin NV, Sidorik LL. Autoantibodies to tryptophanyl-tRNA-synthetase in systemic autoimmune diseases. Mol. Biol. (Mosk.) 32, 745-749 (1998).
7. Hengstman GJ, van Engelen BG, Vree Egberts WT, van Venrooij WJ. Myositis-specific autoantibodies: overview and recent developments. Curr. Opin. Rheumatol. 13, 476-482 (2001).
8. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404, 995-999 (2000).
9. Sun J, Lin Z, Feng J, Li Y, Shen B. BAFF-targeting therapy, a promising strategy for treating autoimmune diseases. Eur. J. Pharmacol. 597, 1-5 (2008).
10. Krystufkova O, Vallerskog T, Helmers SB et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann. Rheum. Dis. 68, 836-843 (2009).
11. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292, 344-347 (1975).
12. Isenberg DA, Allen E, Farewell V et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43, 49-54 (2004).
13. Shu XM, Lu X, Xie Y, Wang GC. Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China. BMC Neurol. 11, 143 (2011).
14. Wang DX, Lu X, Zu N et al. Clinical significance of peripheral blood lymphocyte subsets in patients with polymyositis and dermatomyositis. Clin. Rheumatol. 31, 1691-1697 (2012).
15. Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 48, 3475-3486 (2003).
16. Liu Z, Davidson A. BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp. Cell Res. 317, 1270-1277 (2011).
17. Moisini I, Davidson A. BAFF: a local and systemic target in autoimmune diseases. Clin. Exp. Immunol. 158, 155-163 (2009).
18. Bosello S, Youinou P, Daridon C et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J. Rheumatol. 35, 1256-1264 (2008).
19. Lai Kwan LQ, King Hung KO, Zheng BJ, Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc. Natl Acad. Sci. USA 105, 14993-14998 (2008).
20. Zhang M, Ko KH, Lam QL et al. Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis. Int. Immunol. 17, 1081-1092 (2005).
21. Mariette X, Roux S, Zhang J et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann. Rheum. Dis. 62, 168-171 (2003).
22. Zhao LD, Li Y, Smith MF Jr. et al. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus 19, 1534-1549 (2010).
23. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44, 1313-1319 (2001).
24. Lopez De Padilla CM, McNallan KT, Crowson CS et al. BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies. J. Rheumatol. 40, 294-302 (2013).
25. Baek A, Park HJ, Na SJ et al. The expression of BAFF in the muscles of patients with dermatomyositis. J. Neuroimmunol. 249, 96-100 (2012).
26. Briani C, Doria A, Sarzi-Puttini P, Dalakas MC. Update on idiopathic inflammatory myopathies. Autoimmunity 39, 161-170 (2006).
27. Salajegheh M, Pinkus JL, Amato AA et al. Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles. Muscle Nerve 42, 576-583 (2010).
28. Greenberg SA, Bradshaw EM, Pinkus JL et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 65, 1782-1787 (2005).